MedTrace Logo

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

NCT01461538 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2016-03-04

Study results available
· View outcomes & findings →

Summary

This is an open-label, multicenter, phase 2 clinical trial to evaluate the antitumor activity of brentuximab vedotin as a single agent in patients with CD30-positive nonlymphomatous malignancies.

Conditions

Interventions

DRUG

brentuximab vedotin

1.8 mg/kg every 3 weeks by intravenous (IV) infusion

DRUG

brentuximab vedotin

2.4 mg/kg every 3 weeks by intravenous (IV) infusion

DRUG

brentuximab vedotin

1.2 mg/kg weekly, 3 out of 4 weeks, by intravenous (IV) infusion

Sponsors & Collaborators

  • Seagen Inc.

    lead INDUSTRY

Principal Investigators

  • Neil Josephson, MD · Seagen Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01461538 on ClinicalTrials.gov